Watch the video
- Fully automated analyzer
- Results in just four minutes
- 4 µl sample size required
- Easy to use
Easy and reliable HbA1c measurement
EKF Diagnostics' Quo-Test™ analyzer has been designed for easy and reliable HbA1c measurement for the monitoring and management of diabetes in a point-of-care setting such as diabetes clinics and doctors’ surgeries.
The Quo-Test HbA1c is a fully automated hemoglobin A1c analyzer that uses patented boronate fluorescence quenching technology to measure glycated hemoglobin from a 4 μl sample taken from a finger prick or venous whole blood.
Sample results are available within four minutes and are reported in IFCC and DCCT standard units (Mono S & JDS reporting are also available). Quo-Test is unaffected by most hemoglobin variants.
Quo-Test can store up to 7,000 results which can be downloaded as text files to a PC via the integrated USB interface. Alternatively, results can be printed using a printer which connects via a serial port.
Step by step instructions are displayed on the analyzers clear, multi-lingual display. Staff training time can therefore be minimized and the opportunity for error is reduced.
Quo-Test is CE marked for the monitoring of HbA1c in diabetes patients.
Easy to use
- Intuitive, step by step on screen instructions minimise training time
- Multi-lingual menu
- Just 4 µl blood required from finger prick or venous sample
- Compact: 205 mm (h) x 205 mm (w) x 135 mm (d)
- Lightweight: 1.3 kgs
Fast and accurate
- Results within 4 minutes
- Boronate affinity method which is recognized as interference free
- Measuring range: 4–15 % A1c DCCT
- Imprecision: CV <3 % at 7 % A1c DCCT
- Unaffected by Hb variants, which do not result in reduced erythrocyte life span
- Traceable to the IFCC reference method
Efficient data handling
- Barcode reader included. Only one scan per lot of cartridges required
- Stores up to 7,000 results for efficient patient data management
- User selectable dual reporting. User can select % DCCT, IFCC mmol/mol, eAG mg/dl or eAG mmol/l
- USB port
- Optional label printer available
Sales & marketing
Material safety data sheets
Studies & evaluations
- Quo-Test Collected Studies Summary
- Evaluation of the Quo-Test performance against NGSP criteria and sigma-metrics
- Evaluation of the Quo-Test A1C Assay at the John Radcliffe Hospital
- Study Poster - Assessment of Two PoC Analyzers for Determination of HbA1c
- White Paper - Diabetes Management in a Point-of-Care Setting
- White Paper - Evaluation of Four PoCT Systems (HbA1C)
- Quo-Test - Scandanavian Evaluation of Laboatory Equipment
Frequently asked questions
What is glycated hemoglobin (HbA1c)?
Hemoglobin is an iron containing molecule present in red blood cells that is responsible for transporting oxygen around the body.
Glucose can bind irreversibly to hemoglobin via a process known as glycation. Hemoglobin that has glucose attached is known as glycated hemoglobin, often abbreviated to HbA1c or simply A1c.
How does HbA1c measurement aid the management of diabetes?
Because red blood cells have a life span of 120 days (three months) measuring the level of glycated hemoglobin in blood effectively shows the average blood glucose level for the previous 6-8 weeks.
In conjunction with regular blood glucose monitoring, A1c tests can aid care providers in determining if a patient's treatment plan needs altering in any way to better control blood glucose levels.
Are Quo-Test results traceable to the NGSP and IFCC schemes?
Quo-Test analyzers and tests are calibrated and quality controlled using European Reference Laboratory supplied materials and are traceable to the IFCC reference method.
In an effort to standardize glycated haemoglobin results the AACC established the “National Glycohemoglobin Standardization Program” (NGSP) in 1996. In parallel the International Federation of Clinical Chemistry (IFCC) developed reference methods for glycated hemoglobin.
In 2006 and 2007, an international consensus between IFCC and AACC was agreed upon. The calibration and certification of laboratories and manufacturers to the same standards have improved the conformity of the results.
However, in practice differences can still be observed between technologies as well as between individual systems either because of the heterogeneity of hemoglobins, underlying different technologies (e.g. ion exchange, boronate affinity, immunoassay due to calibration drifts, or lot to lot variability.
This may result in differences in reported values. EKF Diagnostics follows the recommendations of the IFCC and NGSP to ensure that EKF instruments and reagents are accurately aligned and traceable to the reference method. See www.ngsp.org for more information.
What methodology is used?
Quo-Test uses boronate fluorescence quenching, a unique, patented technology, to deliver HbA1c results in four minutes.
What is the advantage of Boronate Fluorescence Quenching Technology (BFQT)?
Based on well documented boronate affinity for glycated hemoglobin, BFQT has similar performance to the boronate affinity chromatography systems used in reference laboratories. Because BFQT does not require chromatographic separation, the methodology allows for fast, simple and accurate point of care HbA1c measurement.
The Quo-Lab system using the BFQT has the advantage of not being affected by hemoglobin variants (which do not result in reduced erythrocyte life span), labile glycated hemoglobin or hematocrit levels.
Quo-Lab™ A1c is a desktop point-of-care analyzer for measuring glycated hemoglobin (HbA1c).
The Biosen can test blood, plasma or serum to provide glucose and lactate values with excellent precision (less than 2% CV) over a wide measurement range.